New 'Living Drug' trial aims to fight advanced cancers that resist other treatments
Disease control
Recruiting now
This study is testing a new type of personalized cell therapy called OBX-115 in adults with advanced melanoma or non-small cell lung cancer that has progressed after standard treatments. Doctors take a patient's own immune cells from a tumor, genetically engineer them to be more …
Phase: PHASE1, PHASE2 • Sponsor: Obsidian Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC